Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ELANE | P08246 | 2/20 | 0.39 |
| ▸ | DGAT2 | Q96PD7 | 12/20 | 0.36 |
| ▸ | GLA | P06280 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.33 |
| ▸ | SLC2A3 | P11169 | 1/20 | 0.33 |
| ▸ | SLC2A4 | P14672 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | TNF | P01375 | 1/20 | 0.32 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15905591 | 0.93 | ELANE (0.38) | ELANEDGAT2GLASMN1; SMN2LMNA | |
| SCHEMBL10089954 | 0.93 | ELANE (0.38) | ELANEDGAT2GLASMN1; SMN2SLC2A1 | |
| SCHEMBL317728 | 0.92 | ELANE (0.37) | ELANEDGAT2GLASMN1; SMN2SLC2A1 | |
| SCHEMBL10089849 | 0.90 | RORC (0.39) | ELANESLC2A1SLC2A3SLC2A4 | |
| SCHEMBL10089479 | 0.88 | ELANE (0.35) | ELANEDGAT2GLASMN1; SMN2LMNA | |
| SCHEMBL13085225 | 0.87 | SLC2A1 (0.37) | ELANESLC2A1SLC2A3SLC2A4 | |
| SCHEMBL317729 | 0.86 | ELANE (0.33) | ELANESLC2A1SLC2A3SLC2A4 | |
| SCHEMBL13085376 | 0.86 | CNR1 (0.37) | ELANESLC2A1SLC2A3SLC2A4 | |
| SCHEMBL10089862 | 0.85 | DGAT2 (0.36) | ELANEDGAT2GLASMN1; SMN2LMNA | |
| SCHEMBL10075531 | 0.84 | CRHR1 (0.37) | SLC2A1SLC2A3SLC2A4IRAK4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8791143-B2 | Anthranilic diamide derivatives having cyclic side-chains | BAYER CROPSCIENCE AG (DE) | 2014-07-29 | — | — | US | disclosed |
| US-20120010249-A1 | Anthranilic diamide derivatives having cyclic side-chains | BAYER CROPSCIENCE AG (DE) | 2012-01-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120010249-A1 | Anthranilic diamide derivatives having cyclic side-chains | DDT, ADCY1, ANTXR2 | ELANE 3872/4885DGAT2 2025/4885GLA 1191/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.